Knights of Columbus Asset Advisors LLC Makes New $739,000 Investment in CG Oncology, Inc. $CGON

Knights of Columbus Asset Advisors LLC purchased a new position in shares of CG Oncology, Inc. (NASDAQ:CGON) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 17,800 shares of the company’s stock, valued at approximately $739,000.

Several other institutional investors and hedge funds have also made changes to their positions in CGON. Whittier Trust Co. of Nevada Inc. purchased a new stake in shares of CG Oncology in the 4th quarter valued at about $27,000. Strengthening Families & Communities LLC purchased a new stake in shares of CG Oncology in the 3rd quarter valued at about $40,000. Comerica Bank lifted its holdings in shares of CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of CG Oncology by 33.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after purchasing an additional 972 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of CG Oncology by 159.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock valued at $182,000 after purchasing an additional 4,288 shares during the last quarter. 26.56% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on CGON shares. JPMorgan Chase & Co. boosted their price target on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Wolfe Research started coverage on CG Oncology in a research report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Truist Financial restated a “buy” rating and issued a $82.00 price target (up from $77.00) on shares of CG Oncology in a research report on Thursday, May 14th. Wedbush boosted their price target on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Finally, HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of CG Oncology in a research report on Monday, May 18th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $81.73.

CG Oncology Trading Up 2.6%

NASDAQ CGON opened at $62.29 on Friday. The business’s 50 day moving average is $66.91 and its two-hundred day moving average is $55.45. CG Oncology, Inc. has a 12-month low of $23.65 and a 12-month high of $75.50. The stock has a market capitalization of $5.49 billion, a price-to-earnings ratio of -26.73 and a beta of 0.41.

CG Oncology (NASDAQ:CGON) last released its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The business had revenue of $1.08 million during the quarter, compared to the consensus estimate of $0.45 million. Equities analysts forecast that CG Oncology, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Buying and Selling at CG Oncology

In related news, Director James Mulay sold 15,600 shares of the company’s stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $73.01, for a total value of $1,138,956.00. Following the sale, the director owned 15,600 shares in the company, valued at $1,138,956. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.80% of the stock is currently owned by corporate insiders.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.